TABLE 2B.
Comparison of patients who did and did not experience delays from surgery to chemotherapy
| Delay from surgery to chemotherapy (n = 1255) | No delay from surgery to chemotherapy (n = 4970) | P | |
|---|---|---|---|
| Age, y | .0012 | ||
| <50 | 291 | 1373 | |
| 50 to 64 | 611 | 2354 | |
| 65 to 74 | 276 | 1030 | |
| 75+ | 77 | 213 | |
| Age, y | .0238 | ||
| <65 | 902 | 3727 | |
| 65+ | 353 | 1243 | |
| Ethnicity | .7718 | ||
| Caucasian | 1149 | 4526 | |
| African-American | 96 | 390 | |
| Other/unknown | 10 | 54 | |
| Year of treatment | .128 | ||
| 2010 to 2013 | 786 | 2996 | |
| 2014 to 2016 | 469 | 1974 | |
| Area of residence | <.0001 | ||
| Metro | 637 | 2846 | |
| Nonmetro | 618 | 2124 | |
| Appalachian status | .0001 | ||
| Appalachia | 407 | 1341 | |
| Non-Appalachia | 848 | 3629 | |
| Education level | <.0001 | ||
| Low | 768 | 2660 | |
| High | 487 | 2310 | |
| Poverty | <.0001 | ||
| Low | 249 | 1229 | |
| Moderate | 266 | 1179 | |
| High | 323 | 1215 | |
| Very high | 417 | 1347 | |
| Insurance status | <.0001 | ||
| Not insured | 28 | 94 | |
| Private | 570 | 2932 | |
| Medicare | 437 | 1389 | |
| Medicaid | 194 | 467 | |
| Other public | 21 | 65 | |
| Unknown | 5 | 23 | |
| Treatment at academic hospital | .1957 | ||
| No | 1094 | 4262 | |
| Yes | 161 | 709 | |
| Tumor size | .3371 | ||
| <3.0 cm | 913 | 3610 | |
| 3.0 to 5.9 cm | 313 | 1275 | |
| ≥6.0 cm | 29 | 85 | |
| Nodes examined | .0025 | ||
| 0 | 80 | 218 | |
| 1 to 11 | 841 | 3560 | |
| 12+ | 322 | 1143 | |
| Unknown | 12 | 49 | |
| Nodes positive | .0662 | ||
| 0 | 636 | 2506 | |
| 1 to 11 | 497 | 2034 | |
| 12+ | 37 | 179 | |
| Unknown | 85 | 251 | |
| Tumor grade | .0027 | ||
| Well-differentiated | 150 | 448 | |
| Moderately differentiated | 496 | 1881 | |
| Poorly differentiated | 579 | 2544 | |
| Undifferentiated | 3 | 14 | |
| Unknown | 27 | 83 | |
| Hormone receptor positive | .0005 | ||
| Negative | 299 | 1459 | |
| Positive | 938 | 3451 | |
| Unknown | 18 | 60 | |
| HER2 positive | .3306 | ||
| Negative | 565 | 2287 | |
| Positive | 155 | 686 | |
| Borderline | 199 | 724 | |
| Unknown | 336 | 1273 | |
| Stage | .0257 | ||
| 0 | 13 | 25 | |
| I | 433 | 1609 | |
| II | 555 | 2372 | |
| III | 209 | 929 | |
| IV | 29 | 79 | |
| Unknown | 16 | 47 | |
| Type of surgery | .0021 | ||
| Lumpectomy | 471 | 2137 | |
| Mastectomy | 783 | 2830 | |
| NOS | 1 | 3 | |
| Reconstruction (Y) | .1989 | ||
| No | 1065 | 4143 | |
| Yes | 190 | 827 | |
Abbreviation: HER2, human epidermal growth factor receptor 2; NOS, not otherwise specified.